The role of pathology in immunotherapy and targeted therapy for renal cell carcinoma
Pathology remains essential for accurate histologic classification, grading, and assessment of adverse features such as sarcomatoid changes and necrosis. Molecular profiling is increasingly helpful in non-clear cell RCC, guiding targeted therapies in subtypes such as MET-driven papillary RCC. Emerging tools (liquid biopsy, spatial transcriptomics, and AI-assisted pathology) offer minimally invasive monitoring, refined immune profiling, and multiparametric biomarker integration to advance precision oncology in RCC.
Authors
- Giuseppe Nicolò Fanelli (ORCID: https://orcid.org/0000-0001-7069-7980)
- Giandomenico Roviello (ORCID: https://orcid.org/0000-0001-5504-8237)
- Gabriella Nesi
Institutions
- University of Pisa (IT)
- Cornell University (US)
- Translational Research in Oncology (FR)
- Azienda Ospedaliera Universitaria Pisana (IT)
- Weill Cornell Medicine (US)
- University of Florence (IT)
Publication Details
- Journal
- Current Opinion in Urology
- Published
- 2025-11-19
- DOI
- https://doi.org/10.1097/mou.0000000000001357
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00